Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 79813
Gene Symbol: EHMT1
EHMT1
0.100 Biomarker disease BEFREE Because of their glycemic efficacy and cardiorenal protection, the GLP-1 RAs will be prominent elements in future diabetes therapy. 31815785 2020
Entrez Id: 2641
Gene Symbol: GCG
GCG
0.100 Biomarker disease BEFREE Because of their glycemic efficacy and cardiorenal protection, the GLP-1 RAs will be prominent elements in future diabetes therapy. 31815785 2020
Entrez Id: 100125288
Gene Symbol: ZGLP1
ZGLP1
0.100 Biomarker disease BEFREE Because of their glycemic efficacy and cardiorenal protection, the GLP-1 RAs will be prominent elements in future diabetes therapy. 31815785 2020
Entrez Id: 2740
Gene Symbol: GLP1R
GLP1R
0.100 Biomarker disease BEFREE Because of their glycemic efficacy and cardiorenal protection, the GLP-1 RAs will be prominent elements in future diabetes therapy. 31815785 2020
Entrez Id: 1401
Gene Symbol: CRP
CRP
0.100 Biomarker disease BEFREE <b><i>Conclusions:</i> Oral health measured by number of tooth extractions >10 was an independent predictor for cerebral infarction in addition to age, HDL-C, hs-C-reactive protein and diabetes. 31814529 2019
Entrez Id: 7133
Gene Symbol: TNFRSF1B
TNFRSF1B
0.060 GeneticVariation disease BEFREE Circulating TNFR-1 and TNFR-2 are independently associated with higher risk of renal disease progression, CVD events, and mortality in patients with diabetes and might contribute to the clinical risk assessment in the future. 31813103 2019
Entrez Id: 7132
Gene Symbol: TNFRSF1A
TNFRSF1A
0.030 GeneticVariation disease BEFREE Circulating TNFR-1 and TNFR-2 are independently associated with higher risk of renal disease progression, CVD events, and mortality in patients with diabetes and might contribute to the clinical risk assessment in the future. 31813103 2019
Entrez Id: 6524
Gene Symbol: SLC5A2
SLC5A2
0.100 Biomarker disease BEFREE In this article we have used consensus expert opinion alongside the available evidence, product indication and most recent clinical guidance to provide support for the diabetes healthcare community regarding the appropriate use of SGLT2 inhibitors, focussing on specific considerations for appropriate prescribing of dapagliflozin within the T1DM management pathway. 31813092 2020
Entrez Id: 9370
Gene Symbol: ADIPOQ
ADIPOQ
0.100 AlteredExpression disease BEFREE Data seem to suggest that lower levels of adiponectin, and higher levels of resistin can be predictive of a future diabetes in obese people, even years before the disease onset. 31811995 2020
Entrez Id: 56729
Gene Symbol: RETN
RETN
0.100 AlteredExpression disease BEFREE Data seem to suggest that lower levels of adiponectin, and higher levels of resistin can be predictive of a future diabetes in obese people, even years before the disease onset. 31811995 2020
Entrez Id: 2864
Gene Symbol: FFAR1
FFAR1
0.100 Biomarker disease BEFREE GPR40 was utilized as the drug target to the treatment of diabetes, but the function and mechanisms ameliorating the Alzheimer's disease (AD) remain unknown. 31809762 2020
Entrez Id: 114548
Gene Symbol: NLRP3
NLRP3
0.100 Biomarker disease BEFREE In this review, we summarise the current understanding of the molecular mechanisms involved in pyroptosis, as well as recent advances in the role of NLRP3 inflammasome activation and pyroptosis in the development of diabetes and diabetic complications. 31809715 2020
Entrez Id: 6476
Gene Symbol: SI
SI
0.100 GeneticVariation disease BEFREE Chalcones, originated from natural product, have been broadly studied their biological activity against various proteins which at the molecular level, are responsible for the progress of the diseases in cancer (e.g. kinases), inflammation (oxidoreductases), atherosclerosis (cathepsins receptor), and diabetes (e.g.α-glucosidase). 31808389 2019
Entrez Id: 8972
Gene Symbol: MGAM
MGAM
0.100 GeneticVariation disease BEFREE Chalcones, originated from natural product, have been broadly studied their biological activity against various proteins which at the molecular level, are responsible for the progress of the diseases in cancer (e.g. kinases), inflammation (oxidoreductases), atherosclerosis (cathepsins receptor), and diabetes (e.g.α-glucosidase). 31808389 2019
Entrez Id: 1803
Gene Symbol: DPP4
DPP4
0.100 Biomarker disease BEFREE Dipeptidyl peptidase 4 (DPP-4) inhibitors have been shown to have neuroprotective effects in diabetic patients suffering from stroke, but less research has focused on patients with mild hyperglycemia below the threshold for a diagnosis of diabetes. 31808042 2019
Entrez Id: 6517
Gene Symbol: SLC2A4
SLC2A4
0.100 AlteredExpression disease BEFREE Impaired expression of GLUT4 has been linked to insulin resistance and diabetes. 31806561 2020
Entrez Id: 10062
Gene Symbol: NR1H3
NR1H3
0.010 Biomarker disease BEFREE The study is of much relevance in treatment of diabetes and also opens the possibility of identifying new drug molecules that target LXRα. 31806561 2020
Entrez Id: 4151
Gene Symbol: MB
MB
0.010 Biomarker disease BEFREE Proteins associated with DKD were also assessed as predictors for incident major adverse cardiovascular events (MACE) in persons with DKD at baseline.<b>Results:</b> Four proteins were positively associated with DKD in models adjusted for age, sex, cardiovascular risk factors, glucose control, and diabetes medication: kidney injury molecule-1 (KIM-1, odds ratio [OR] per standard deviation increment, 1.65, 95% confidence interval [CI] 1.27-2.14); growth differentiation factor 15 (GDF-15, OR 1.40, 95% CI 1.16-1.69); myoglobin (OR 1.57, 95% CI 1.30-1.91), and matrix metalloproteinase 10 (MMP-10, OR 1.43, 95% CI 1.17-1.74). 31805809 2020
Entrez Id: 55364
Gene Symbol: IMPACT
IMPACT
0.030 GeneticVariation disease BEFREE Title: Development of the Influence, Motivation, and Patient Activation in Diabetes (IMPACT-D™) Measure. 31805349 2020
Entrez Id: 4018
Gene Symbol: LPA
LPA
0.200 GeneticVariation disease BEFREE This study assessed associations of diet quality (evaluated using the Alternative Healthy Eating Index (AHEI)), and the interaction of diet quality with diabetes, on total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL-C), high-density lipoprotein (HDL-C), apolipoprotein A (apoA1), and apolipoprotein B (apoB) among American Indians (AIs). 31804627 2019
Entrez Id: 338
Gene Symbol: APOB
APOB
0.070 Biomarker disease BEFREE This study assessed associations of diet quality (evaluated using the Alternative Healthy Eating Index (AHEI)), and the interaction of diet quality with diabetes, on total cholesterol (TC), triglycerides (TG), low-density lipoprotein (LDL-C), high-density lipoprotein (HDL-C), apolipoprotein A (apoA1), and apolipoprotein B (apoB) among American Indians (AIs). 31804627 2019
Entrez Id: 3553
Gene Symbol: IL1B
IL1B
0.100 Biomarker disease BEFREE Additionally, the importance of IL-1β in modulating the inflammatory response after corneal injury in patients with diabetes and controls was further elucidated. 31803484 2019
Entrez Id: 22852
Gene Symbol: ANKRD26
ANKRD26
0.010 Biomarker disease BEFREE Ankyrin Repeat Domain 26 (Ankrd26) is involved in the development of both obesity and diabetes in mice and is modulated by environmentally induced epigenetic modifications. 31801613 2019
Entrez Id: 64805
Gene Symbol: P2RY12
P2RY12
0.040 Biomarker disease BEFREE Factors associated with higher rates of POMI were age (odds ratio [OR], 1.032 [95% CI, 1.019-1.045]; P < .001), diabetes (OR, 1.514 [95% CI, 1.201-1.907]; P < .001), congestive heart failure (OR, 1.519 [95% CI, 1.163-1.983]; P = .002), valvular disease (OR, 1.447 [95% CI, 1.024-2.046]; P = .04), coronary artery disease (OR, 1.381 [95% CI, 1.058-1.803]; P = .02), and preoperative P2Y12 antagonist use (OR, 1.37 [95% CI, 1.08-1.725]; P = .009). 31800003 2019
Entrez Id: 3569
Gene Symbol: IL6
IL6
0.100 GeneticVariation disease BEFREE After adjustment for race, age, gender, body mass index (BMI), diabetes, smoking, HIV RNA and CD4+ levels, associations of IL-6 and hsCRP with HTN prevalence were not significant (OR per twofold higher:1.10, 95% confidence interval [CI]: 0.99, 1.20 for IL-6 and 1.05, 95% CI: 0.99, 1.10 for hsCRP). 31800000 2020